Wegovy lowers BMI in children in trial
Novo Nordisk said Wegovy lowered BMI and obesity rates in children in a trial. No drug is approved for children under 12.
Why it matters
Younger children may gain a treatment option.
Background
Wegovy is approved for ages 12 and over.
The story so far
- Wegovy lowers BMI in children in trial
- Novo says Wegovy lowers BMI in children in trial
Sources
- CNBC ↗Nov 16, 10:00 AM ET
This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.